Conflicting Roles of Molecules in Hepatocarcinogenesis: Paradigm or Paradox

Cancer Cell

Volumn 21, Issue 2, 2012, Pages 150-154

  Feng, Gen Sheng ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN;

CELL COMMUNICATION; CELL DAMAGE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER INJURY; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW;

EID: 84856994812     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.01.001     Document Type: Review

References (32)

1. Aleksic K., Lackner C., Geigl J.B., Schwarz M., Auer M., Ulz P., Fischer M., Trajanoski Z., Otte M., Speicher M.R. Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. Hepatology 2011, 53:895-904.
2. Bard-Chapeau E.A., Li S., Ding J., Zhang S.S., Zhu H.H., Princen F., Fang D.D., Han T., Bailly-Maitre B., Poli V., et al. Ptpn11/Shp2 acts asa tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011, 19:629-639.
3. Bettermann K., Vucur M., Haybaeck J., Koppe C., Janssen J., Heymann F., Weber A., Weiskirchen R., Liedtke C., Gassler N., et al. TAK1 suppresses a NEMO-dependent but NF-κB-independent pathway to liver cancer. Cancer Cell 2010, 17:481-496.
4. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4:915-925.
5. Calvisi D.F. Dr. Jekyll and Mr. Hyde: a paradoxical oncogenic and tumor suppressive role of signal transducer and activator of transcription 3 in liver cancer. Hepatology 2011, 54:9-12.
6. Das M., Garlick D.S., Greiner D.L., Davis R.J. The role of JNK inthe development of hepatocellular carcinoma. Genes Dev. 2011, 25:634-645.
7. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A., Perret C. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA 1998, 95:8847-8851.
8. Galicia V.A., He L., Dang H., Kanel G., Vendryes C., French B.A., Zeng N., Bayan J.A., Ding W., Wang K.S., et al. Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2. Gastroenterology 2010, 139:2170-2182.
9. Haybaeck J., Zeller N., Wolf M.J., Weber A., Wagner U., Kurrer M.O., Bremer J., Iezzi G., Graf R., Clavien P.A., et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009, 16:295-308.
10. He G., Yu G.Y., Temkin V., Ogata H., Kuntzen C., Sakurai T., Sieghart W., Peck-Radosavljevic M., Leffert H.L., Karin M. Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010, 17:286-297.
11. Horiguchi N., Wang L., Mukhopadhyay P., Park O., Jeong W.I., Lafdil F., Osei-Hyiaman D., Moh A., Fu X.Y., Pacher P., et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008, 134:1148-1158.
12. Hui L., Zatloukal K., Scheuch H., Stepniak E., Wagner E.F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 2008, 118:3943-3953.
13. Lin L., Amin R., Gallicano G.I., Glasgow E., Jogunoori W., Jessup J.M., Zasloff M., Marshall J.L., Shetty K., Johnson L., et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene 2009, 28:961-972.
14. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., Roskams T., Trautwein C., Pasparakis M. Deletion of NEMO/IKKγ in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11:119-132.
15. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
16. Nejak-Bowen K.N., Monga S.P. β-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin. Cancer Biol. 2011, 21:44-58.
17. Nejak-Bowen K.N., Thompson M.D., Singh S., Bowen W.C., Dar M.J., Khillan J., Dai C., Monga S.P. Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant β-catenin. Hepatology 2010, 51:1603-1613.
18. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
19. Sakurai T., Maeda S., Chang L., Karin M. Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. USA 2006, 103:10544-10551.
20. Sakurai T., He G., Matsuzawa A., Yu G.Y., Maeda S., Hardiman G., Karin M. Hepatocyte necrosis induced by oxidative stress and IL-1α release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008, 14:156-165.
21. Schneller D., Machat G., Sousek A., Proell V., van Zijl F., Zulehner G., Huber H., Mair M., Muellner M.K., Nijman S.M., et al. p19(ARF)/p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology 2011, 54:164-172.
22. Takami T., Kaposi-Novak P., Uchida K., Gomez-Quiroz L.E., Conner E.A., Factor V.M., Thorgeirsson S.S. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine-induced hepatocarcinogenesis. Cancer Res. 2007, 67:9844-9851.
23. van Hogerlinden M., Auer G., Toftgård R. Inhibition of Rel/Nuclear Factor-κB signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development. Oncogene 2002, 21:4969-4977.
24. Verna L., Whysner J., Williams G.M. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol. Ther. 1996, 71:57-81.
25. Wang E.Y., Yeh S.H., Tsai T.F., Huang H.P., Jeng Y.M., Lin W.H., Chen W.C., Yeh K.H., Chen P.J., Chen D.S. Depletion of β-catenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development. Proc. Natl. Acad. Sci. USA 2011, 108:18384-18389.
26. Wang H., Lafdil F., Wang L., Park O., Yin S., Niu J., Miller A.M., Sun Z., Gao B. Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis. Am. J. Pathol. 2011, 179:714-724.
27. Wang R., Ferrell L.D., Faouzi S., Maher J.J., Bishop J.M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 2001, 153:1023-1034.
28. Yamaji S., Zhang M., Zhang J., Endo Y., Bibikova E., Goff S.P., Cang Y. Hepatocyte-specific deletion of DDB1 induces liver regeneration and tumorigenesis. Proc. Natl. Acad. Sci. USA 2010, 107:22237-22242.
29. You H., Ding W., Dang H., Jiang Y., Rountree C.B. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011, 54:879-889.
30. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
31. Yue P., Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin. Investig. Drugs 2009, 18:45-56.
32. Zhang X.F., Tan X., Zeng G., Misse A., Singh S., Kim Y., Klaunig J.E., Monga S.P. Conditional β-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor α/phosphoinositide 3-kinase signaling. Hepatology 2010, 52:954-965.